Searchable abstracts of presentations at key conferences on calcified tissues

ba0003cu2.2 | Management of parathyroid diseases | ECTS2014

Primary hyperparathyroidism: epidemiology and diagnosis

Eastell Richard

The purpose of this presentation is to present the guidelines for recommending surgery for asymptomatic primary hyperparathyroidism, based on a workshop held in 2013. The indications for surgery were: i) a serum calcium more than 1 mg/dl (or 0.25 mmol/l) above the reference interval; ii) a low bone density (T-score −2.5 or less at the lumbar spine, total hip, femoral neck, or distal radius 1/3) or presence of vertebral fracture; iii) chronic kidney disease stage...

ba0001pp58 | Bone biomechanics and quality | ECTS2013

Diagnostic discrimination of TBS and spine BMD in glucocorticoid-induced and postmenopausal osteoporosis

Paggiosi Margaret , Peel Nicola , Eastell Richard

Glucocorticoids inhibit osteoblast function and cause an increase in osteoblast and osteocyte apoptosis. Bone remodelling defects occur resulting in an increase in fracture risk that cannot be fully explained by decreases in bone mineral density (BMD). We propose that this may be due to alterations in bone quality. Trabecular bone score (TBS) correlates with 3D bone micro-architectural parameters and can be derived directly from grey-level variations within 2D DXA images.<...

ba0003pp209 | Muscle, physical activity and bone | ECTS2014

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

Evans Amy , Eastell Richard , Walsh Jennifer

Obesity is associated with greater risk of proximal humerus and ankle fracture, despite greater areal BMD (aBMD). We aimed to investigate whether greater risk of some fractures in obesity was due to skeletal or non-skeletal determinants. 100 individually-matched pairs of normal weight (NW) (18.5–24.9 kg/m2) and obese (OB) (BMI >30 kg/m2) individuals, aged 25–40 and 55–75 years underwent DXA to determine hip and lumbar spine aBMD, whole ...

ba0003pp386 | Other diseases of bone and mineral metabolism | ECTS2014

Bone mineral density and micro-architectural changes in advanced chronic kidney disease

Salam Syazrah , Khwaja Arif , Eastell Richard

Background: Risk of fracture in chronic kidney disease (CKD) population is high and it is associated with increased mortality. CKD affects bone quality through changes in bone turnover, microarchitecture, and mineralization. Secondary hyperparathyroidism has different effects on cortical and trabecular bone but dual-energy X-ray absorptiometry (DXA) is unable to effectively differentiate these bone compartments. High resolution peripheral quantitative computed tomography (HRpQ...

ba0005p403 | Osteoporosis: treatment | ECTS2016

Biochemical monitoring of teriparatide efficacy in a real world setting

Pigott Thomas , Eastell Richard , Peel Nicola

Teriparatide is an anabolic agent given to reduce fracture risk in osteoporosis; it increases BMD and bone turnover. For monitoring treatment efficacy, serum PINP shows the greatest increase and low variability; it has been proposed as a marker of individual treatment response. We aimed to evaluate the utility of PINP to monitor teriparatide treatment in clinical practice.We performed a retrospective evaluation of 91 patients treated with teriparatide si...

ba0005p454 | Other diseases of bone and mineral metabolism | ECTS2016

Bone mineral density and vascular calcification in obesity

Bouquegneau Antoine , Walsh Jennifer , Evans Amy , Paggiosi Margaret , Eastell Richard

Background: The presence of vascular calcification (VC) is a predictive factor for the development of cardiovascular diseases, especially in the obese population. VC has also been inversely associated with bone mineral density (BMD) but the results have been inconsistent. The main aim of this study was to evaluate the associations between VC, obesity and volumetric BMD (vBMD).Methods: We studied 148 healthy men and women, aged 55–75 years, divided i...

ba0003oc6.5 | Osteoporosis treatment and the effects of physical activity | ECTS2014

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study

Gossiel Fatma , Hoyle Christopher , McCloskey Eugene , Walsh Jennifer , Peel Nicola , Eastell Richard

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...